Standard BioTools Inc. Announces Strategic Sale of SomaLogic to Illumina

On June 23, 2025, Standard BioTools Inc., a health care company specializing in life sciences tools and services, announced the sale of its SomaLogic division to Illumina for up to $425 million. This strategic move marks a significant transformation for the company, as highlighted by multiple financial news sources.

SomaLogic, a key division of Standard BioTools, is known for its innovative technologies in mass cytometry and microfluidics. The sale to Illumina, a leader in genomics and digital biology, is expected to bolster both companies’ capabilities in advancing health and disease research.

The transaction has been well-received in the financial markets, with Standard BioTools’ stock experiencing a notable increase following the announcement. This positive market reaction underscores investor confidence in the strategic direction of the company.

Standard BioTools, headquartered in South San Francisco, United States, is listed on the Nasdaq stock exchange. As of June 19, 2025, the company’s close price was $1.05, with a market capitalization of approximately $414 million. Despite a negative price-to-earnings ratio of -3.13, the sale of SomaLogic is anticipated to enhance the company’s financial standing and operational focus.

The company, which went public on February 10, 2011, aims to transform scientific discoveries into better patient outcomes. With this sale, Standard BioTools is entering a new phase of its business strategy, focusing on its core competencies in mass cytometry and microfluidics technologies.

This strategic sale is expected to have a significant impact on the life sciences tools and services sector, as both Standard BioTools and Illumina continue to innovate and expand their research capabilities.